Use of loop diuretics in heart failure: Current aspects


Cite item

Full Text

Abstract

Loop diuretics take the lead in the treatment of patients with symptomatic heart failure. Torasemide is the most effective and safe loop diuretic with the optimal pharmacokinetic profile, the additional properties associated with simultaneous blockade of the renin-angiotensin-aldosterone system and with the antiadrenergic effects of the drug, its positive impact on myocardial fibrosis and minimal severe potential negative effects. Sustained-release torasemide provides a more comfortable removal of excess liquid and does not deteriorate quality of life.

About the authors

N V Kurlykina

Медицинский научно-образовательный центр ФГБОУ ВО МГУ им. М.В. Ломоносова

Москва, Россия

E M Seredenina

Медицинский научно-образовательный центр ФГБОУ ВО МГУ им. М.В. Ломоносова

Москва, Россия

Yа A Orlova

Медицинский научно-образовательный центр ФГБОУ ВО МГУ им. М.В. Ломоносова

Москва, Россия

References

  1. Jessup M, Abraham WT, Casey DE, Feldman AM, Francis GS, Ganiats TG, Konstam MA, Mancini DM, Rahko PS, Silver MA, Stevenson LW, Yancy CW. 2009 Focused Update: ACCF/AHA Guidelines for the Diagnosis and Management of Heart Failure in Adults: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: Developed in Collaboration With the International Society for Heart and Lung Transplantation. Circulation. 2009;119:1977-2016. https://doi.org/10.1161/circulationaha.109.192064
  2. Мареев В.Ю., Агеев Ф. Т., Арутюнов Г.П., Коротеев А.В., Мареев Ю.В., Овчинников А.Г., Беленков Ю.Н., Васюк Ю.А., Галявич А.С., Гарганеева А.А., Гиляревский С.Р., Глезер М.Г., Козиолова Н.А., Коц Я.И., Лопатин Ю.М., Мартынов А.И., Моисеев В.С., Ревишвили А.Ш., Ситникова М.Ю., Скибицкий В.В., Соколов Е.И., Сторожаков Г.И., Фомин И.В., Чесникова А.И., Шляхто Е.В., Акчурин Р.С., Аронов Д.М., Архипов М.В., Барт Б.Я., Белоусов Ю.Б., Бойцов С.А., Гендлин Г.Е., Голиков А.П., Голицын С.П., Гуревич М.А., Даниелян М.О., Довгалевский П.Я., Задионченко В.С., Карпов Р.С., Карпов Ю.А., Кобалава Ж.Д., Кузнецов В.А., Лазебник Л.Б., Насонов Е.Л., Недогода С.В., Никитин Ю.П., Оганов Р.Г., Панченко Е.П., Перепеч Н.Б., Подзолков В.И., Поздняков Ю.А., Раков А.Л., Руда М.Я., Рылова А.К., Симоненко В.Б., Сидоренко Б.А., Староверов И.И., Сулимов В.А., Тарловская Е.И., Терещенко С.Н., Фомина И.Г., Чазова И.Е., Драпкина О.М. Национальные рекомендации ОССН, РКО и РНМОТ по диагностике и лечению ХСН (четвертый пересмотр). Сердечная недостаточность. 2013;14;7(81):1-94.
  3. Arueira HB, Mesquita ET, Kang HC, Miranda VA, Ramos CS, Rosa MLG. Low quality of life as an additional criterion for the clinical diagnosis of heart failure in primary care. Rev Port Cardiol. 2012;31(9):559-565. https://doi.org/10.1016/j.repc.2012.06.004
  4. Roger VL, Go AS, Lloyd-Jones DM, Benjamin EJ, Berry JD, Borden WB, Bravata DM, Dai S, Ford ES, Fox CS, Fullerton HJ, Gillespie C, Hailpern SM, Heit JA, Howard VJ, Kissela BM, Kittner SJ, Lackland DT, Lichtman JH, Lisabeth LD, Makuc DM, Marcus GM, Marelli A, Matchar DB, Moy CS, Mozaffarian D, Mussolino ME, Nichol G, Paynter NP, Soliman EZ, Sorlie PD, Sotoodehnia N, Turan TN, Virani SS, Wong ND, Woo D, Turner MB, on behalf of the American Heart Association Statistics Committee and Stroke Statistics Subcommittee, On behalf of the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Executive summary: heart disease and stroke statistics-2012 update: a report from the American Heart Association. Circulation. 2012;125(1):188-197. https://doi.org/10.1161/cir.0b013e3182456d46
  5. Vaduganathan M, Fonarow GC. Epidemiology of hospitalized heart failure: differences and similarities between patients with reduced versus preserved ejection fraction. Heart Fail Clin. 2013;9(3):271-276. https://doi.org/10.1016/j.hfc.2013.04.001
  6. Гуревич М.А. Хроническая сердечная недостаточность: Руководство для врачей. М.: МИА; 2005:280.
  7. Cleland JG, Tendera M, Adamus J, Freemantle N Polonski L Taylor J. The perindopril in elderly people with chronic heart failure (PEP-CHF) study. Eur Heart J. 2006;27(19):2338-2345. https://doi.org/10.1093/eurheartj/ehl250
  8. Cody RJ, Kubo SH, Pickworth KK. Diuretic treatment for the sodium retention of congestive heart failure. Arch Intern Med. 1994;154:1905-1914. https://doi.org/10.1001/archinte.1994.00420170045004
  9. Coletta AP, Clark AL, Cleland JG. Clinical trials update from the Heart Failure Society of America and the American Heart Association meetings in 2008: SADHART-CHF, COMPARE, MOMENTUM, thyroid hormone analogue study, HF-ACTION, I-PRESERVE, beta-interferon study, BACH, and ATHENA. Eur J Heart Fail. 2009; 11(2):214-219. https://doi.org/10.1093/eurjhf/hfn047
  10. Drechsler K, Dietz R, Klein H, Wollert KC, Storp D, Molling J, Zeymer U, Niebauer J. Euro heart failure survey. Medical treatment not in line with current guidelines. Z Kardiol. 2005;94(8):510-515. https://doi.org/10.1007/s00392-005-0245-y
  11. Фомин И.В., Беленков Ю.Н., Мареев В.Ю., Агеев Ф.Т., Бадин Ю.В., Галявич А.С., Даниелян М.О., Камалов Г.М., Колбин А.А., Кечеджиева С.Г., Макарова В.Г., Макарова .В., Маленкова В.Ю., Сайфутдинов Р.И., Тарловская Е.И., Хохлов Р.А., Щербинина Е.В., Якушин С.С. Распространенность хронической сердечной недостаточности в Европейской части Российской Федерации — данные ЭПОХА-ХСН. Сердечная недостаточность. 2006;7(1):112-115.
  12. Фомин И.В., Беленков Ю.Н., Мареев В.Ю., Агеев Ф.Т., Бадин Ю.В., Галявич А.С., Даниелян М.О., Камалов Г.М., Колбин А.А., Кечеджиева С.Г., Макарова В.Г., Макарова Н.В., Маленкова В.Ю., Сайфутдинов Р.И., Тарловская Е.И., Хохлов Р.А., Щербинина Е.В., Якушин С.С. Распространенность хронической сердечной недостаточ-ности в Европейской части Российской Федерации — данные ЭПОХА-ХСН (часть 2). Сердечная недостаточность. 2006;7(3):3-7.
  13. Мареев В.Ю., Агеев Ф.Т., Арутюнов Г.П. и др. Национальные рекомендации ОССН, РКО и РНМОТ по диагностике и лечению ХСН. Сердечная недостаточность. 2013;14;7(81):1-91.
  14. Brater D. Torasemide: pharmacokinetic and clinical efficacy. Eur J Heart Fail. 2001;3(Suppl.G):19-24.
  15. Fortuno A, Muniz P, Ravassa S, Rodriguez JA, Fortuno M A, Zalba G, Diez J. Torasemide inhibits angiotensin II-induced vasoconstriction and intracellular calcium increase in the aorta of spontaneously hypertensive rats. Hypertension. 1999;34:138-143. https://doi.org/10.1161/01.hyp.34.1.138
  16. Kasama S, Toyama T, Hatori T, Sumino H, Kumakura H, Takayama Y, Ichikawa S, Suzuki T, Kurabayashi M. Effects of torasemide on cardiac sympathetic nerve activity and left ventricular remodeling in patients with congestive heart failure. Heart. 2006;92:1434-1440. https://doi.org/10.1136/hrt.2005.079764
  17. Harada K, Izawa H, Nishizawa T, Hirashiki A, Murase Y, Kobayashi M, Isobe S, Cheng XW, Noda A, Nagata K, Yokota M, Murohara T. Beneficial effects of torasemide on systolic wall stress and sympathetic nervous activity in asymptomatic or mildly symptomatic patients with heart failure: comparison with azosemide. J Cardiovasc Pharmacol. 2009;53:468-473. https://doi.org/10.1097/fjc.0b013e3181a717f7
  18. Bolke T, Achhammer I. Torasemide review of its pharmacology and therapeutic use. Drugsof Today. 1994;30(8):1-28.
  19. Uchida T, Yamanaga K, Nishikawa M, Ohtaki Y, Kido H, Watanabe M. Anti-aldosteronergic effect of torasemide. Eur J Pharmacol. 1991;205:145-150. https://doi.org/10.1016/0014-2999(91)90812-5
  20. Goodfriend TL, Ball DL, Oelkers W, Bahr V. Torsemide inhibits aldosterone secretion in vitro. Life Sci. 1998;63:PL45-50. https://doi.org/10.1016/s0024-3205(98)00265-3
  21. Yamato M, Sasaki T, Honda K, Fukuda M, Akutagawa O, Okamoto M, Hayashi T. Effects of torasemide on left ventricular function and neurohumoral factors in patients with chronic heart failure. Circ J. 2003;67 (5):384-390. https://doi.org/10.1253/circj.67.384
  22. Domanski M, Norman J, Pitt B, Haigney M, Hanlon S, Peyster E. Diuretic use, progressive heart failure, and death in patients in the Studies of Left Ventricular Dysfunction (SOLVD). J Am Coll Cardiol. 2003;42:705-708. https://doi.org/10.1016/S0735-1097(03)00765-4
  23. Cosin J, Diez J. Torasemide in chronic heart failure: results of the TORIC study. Eur J Heart Fail. 2002;4:507-513. https://doi.org/10.1016/s1388-9842(02)00122-8
  24. Murray MD, Deer MM, Ferguson JA, Dexter PR, Bennett SJ, Perkins SM, Smith FE, Lane KA, Adams LD, Tierney WM, Brater DC. Open-label randomized trial of torsemide compared with furosemide therapy for patients with heart failure. Am J Med. 2001;111:513-520. https://doi.org/10.1016/s0002-9343(01)00903-2
  25. Мареев В.Ю., Выгодин В.А., Беленков Ю.Н. Диуретическая терапия эффективными дозами пероральных диуретиков торасемида и фурасемида в лечении больных с обострением хронический сердечной недостаточности (ДУЭЛЬ-ХСН). Сердечная недостаточность. 2011;12,№1(63):1-9.
  26. Muller K, Gamba G, Jaquet F, Hess B. Torasemide vs. furosemide in primary care patients with chronic heart failure NYHA II to IV efficacy and quality of life. Eur J Heart Fail. 2003;5:793-801. https://doi.org/10.1016/s1388-9842(03)00150-8
  27. DiNicolantonio JJ. Should torsemide be the loop diuretic of choice in systolic heart failure? Future Cardiol. 2012;8:707-728. https://doi.org/10.2217/fca.12.54
  28. Dominik G. Haider, Gregor Lindner, et al. Use of Diuretics is not associated with mortality in patients admitted to the emergency department: results from a cross-sectional study. J Negat Results Biomed. 2016;15:1. https://doi.org/10.1186/s12952-016-0044-1
  29. Robert J Mentz, Eric J Velazquez, Metra M, McKendry C, Chiswell K, Fiuzat M, Givertz MM, Voors AA, Teerlink JR, O’Connor CM. Comparative effectiveness of torsemide versus furosemide in heart failure patients: insights from the PROTECT trial September 2015,Vol. 11, No. 5, Pages 585-595. https://doi.org/10.2217/fca.15.56
  30. Mentz RG, Hasselblad V, DeVore AD, Metra M, Voors AA, Armstrong PW, Ezekowitz JA, Tang WHW, Schulte PJ, Anstrom KJ, Hernandez AF, Velazquez EJ, O’Connor CM. Torsemide versus Furosemide in Patients with Acute Heart Failure (From the ASCEND-HF Trial). Am J Cardiol. 2016;117(3):404-411. https://doi.org/10.1016/j.amjcard.2015.10.059
  31. Lopez B, Querejeta R, Gonzalez A, Sanchez E, Larman M, Diez J. Effects of loop diuretics on myocardial fibrosis and collagen type I turnover in chronic heart failure. J Am Coll Cardiol. 2004;43:2028-2035. https://doi.org/10.1016/j.jacc.2003.12.052
  32. Lopez B, Gonzalez A, Beaumont J, Querejeta R, Larman M, Diez J. Identification of a potential cardiac antifibrotic mechanism of torasemide in patients with chronic heart failure. J Am Coll Cardiol. 2007;50:859-867. https://doi.org/10.1016/j.jacc.2007.04.080
  33. López B, Querejeta R, González A, Beaumont J, Larman M, Diez J. Impact of treatment on myocardial lysyl oxidase expression and collagen cross-linking in patients with heart failure. Hypertension. 2009;53(2):236-242. https://doi.org/10.1161/hypertensionaha.108.125278
  34. Han LN, Guo SL, Lin XM, Shi XM, Zang CB, Yang LM, Ding GL. Torasemide reduces dilated cardiomyopathy, complication of arrhythmia, and progression to heart failure. Genet Mol Res. 2014;13(3):7262-7274. https://doi.org/10.4238/2014.september.5.11
  35. Effects of Prolonged-Release Torasemide Versus Furosemide on Miocardial Fibrosis in Hypertensive Patients with Chronic Heart Failure: A Randomized, Blinded-End Point. Active-Controlled Study. The TORAFIC Investigators Group. Clin Ther. 2011;33: 1204-1213. https://doi.org/10.1016/j.clinthera.2011.08.006
  36. Tsutamoto T., Sakai H., Wada A., Ishikawa C., Ohno K., Fujii M., Yamamoto T., Takayama T., Dohke T., Horie M. Torasemide inhibits transcardiac extraction of aldosterone in patients with congestive heart failure. J Am Coll Cardiol. 2004;44:2252-2253. https://doi.org/10.1016/j.jacc.2004.09.009
  37. Adam O, Zimmer C, Hanke N, Hartmann RW, Klemmer B, Böhm M, Laufs U. Inhibition of aldosterone synthase (CYP11B2) by torasemide prevents atrial fibrosis and atrial fibrillation in mice. J Mol Cell Cardiol. 2015;85:140-150. https://doi.org/10.1016/j.yjmcc.2015.05.019
  38. Gropper S, Albet C, Guglietta A. Single-dose, randomized, cross-over, bioavailability pilot clinical trial of torasemide immediate release compared to a new prolonged release formulation of torasemide . Basic Clin Pharmacol Toxicol. 2006;99(Suppl.1):48.
  39. Barbanoj MJ, Ballester MR, Antonijoan RM, Gich I, Pelagio P, Gropper S, Santos B, Guglietta A. Comparison of repeated-dose pharmacokinetics of prolonged-release and immediate-release torasemide formulations in healthy young volunteers. Fundam Clin Pharmacol. 2009;23(1):115-125. https://doi.org/10.1111/j.1472-8206.2008.00643.x
  40. Reyes А. Effects of diuretics on renal excretory function. Eur Heart J. 1992;13(Suppl.G):15021. https://doi.org/10.1093/eurheartj/13.suppl_g.15
  41. Арутюнов Г.П., Оганезова Л.Г., Драгунов Д.О. Взаимосвязь периода полувыведения петлевого диуретика, выраженности натрийуреза и показателей центральной гемодинамики у больных ХСН (пилотное исследование). Сердечная недостаточность. 2012;(13):4(72):222-227. https://doi.org/10.18087 / rhfj.2012.4.1715
  42. Арутюнов А.Г., Драгунов Д.О., Арутюнов Г.П., Рылова А.К., Соколова А.В. Влияние лекарственных форм петлевого диуретика с различной скоростью высвобождения на ранний и отсроченный прогноз у пациентов с декомпенсацией кровообращения. Кардиология. 2014;(9):24-32.

Copyright (c) 2017 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
 
 


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies